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Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by a functional 
deterioration of the brain. Currently, there are selected biomarkers for its diagnosis in cerebrospinal 
fluid. However, its extraction has several disadvantages for the patient. Therefore, there is an urgent 
need for a detection method using sensitive and selective blood-based biomarkers. Kynurenic acid 
(KYNA) is a potential biomarker candidate for this purpose. The alteration of the KYNA levels in 
blood has been related with inflammatory processes in the brain, produced as a protective function 
when neurons are damaged This paper describes a novel electrochemical immunosensor for KYNA 
detection, based on successive functionalization multi-electrode array. The resultant sensor was 
characterized by cyclic voltammetry (CV), chronoamperometry (CA), and electrochemical imped-
ance spectroscopy (EIS). The proposed biosensor detects KYNA within a linear calibration range 
from 10 pM to 100 nM using CA and EIS, obtaining a limit of detection (LOD) of 16.9 pM and 37.6 
pM in buffer, respectively, being the lowest reported LOD for this biomarker. Moreover, to assess 
our device closer to the real application, the developed immunosensor was also tested under human 
serum matrix, obtaining an LOD of 391.71 pM for CA and 278.8 pM for EIS with diluted serum. 
Keywords: Alzheimer’s disease (AD); immunosensor; kynurenic acid (KYNA); electrochemical bi-
osensor; chronoamperometry (CA); electrochemical impedance spectroscopy (EIS), blood analysis; 
point of care diagnosis (PoC), in vitro diagnosis (IVD) 
 
1. Introduction 
Alzheimer’s disease (AD) is the primary common cause of dementia in people over 
the age of 60, and the 3rd leading cause of death for the elderly population. Several AD 
parameters, such as incidence and prevalence, are age dependent and as the world’s life 
expectancy has been rising, AD has become one of the main universal healthcare prob-
lems. In 2020, more than 50 million people worldwide suffer from dementia, and is esti-
mated to be triple in 2050 with the aging of the population [1,2]. 
AD is a progressive deterioration of the neuronal cells until their death, being cur-
rently incurable. This disease is mainly characterized by the abnormal accumulation of 
extracellular amyloid in plaques, where its main component is the amyloid beta peptide 
(Aβ42). Additionally, intraneuronal neurofibrillary tangle aggregates, formed by hyper-
phosphorylated tau (P-𝜏) protein, are accumulated in the cerebral vasculature, with a 
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subsequent loss of neuronal and synaptic activity in selected brain areas. Due to these 
alterations, astrocytes and microglia are activated, resulting in neuroinflammation and 
the death of neurons [3,4]. 
The symptoms of AD appear many years after the illness has started. A study of peo-
ple with a genetic mutation that develops the disease with similar timing as the non-ge-
netic AD patients found that the levels of Aβ42 were increased 22 years before symptoms, 
and the atrophy of their brains occurred 13 years before alarms appeared [5]. Therefore, 
this long asymptomatic phase causes a delay in the AD diagnosis, which happens at an 
advanced stage, reducing the possibility of a successful prognosis. Consequently, a key 
factor would be to develop early detection methods for AD. 
The concentration of Aβ42 at the beginning of the disease is comparable to heathy con-
trols. However, the concentration of this amyloid is reduced 10 years before symptoms 
appear, being confirmed as a relevant biomarker in early phases. Due to the glymphatic 
system, which cleanses the waste molecules inside the brain, toxic neurodegenerative pro-
teins are also present in the blood. The access to this peripheral fluid is easier, riskless, and 
has a lower cost than cerebrospinal fluid (CSF) extraction by lumbar puncture. However, 
the Aβ42 in blood is 10 times less concentrated than in CSF [6]. Therefore, another im-
portant point in this disease is to find early detection biomarkers in blood at detectable 
levels. 
Inflammatory processes in the brain greatly influence several systems underlying the 
disease progression. One of the main biochemical alterations occurs in the kynurenine 
pathway of tryptophan metabolism. This pathway generates several neuroactive com-
pounds, including the metabolite kynurenic acid (KYNA), which is synthesized from 
kynurenine through kynurenine aminotransferases (KAT) I and II [7]. The potential in-
volvement of KYNA in neurodegenerative disorders (NDDs) has been described, with 
potential links between KYNA levels and commonly used AD biomarkers (Aβ, total tau 
(T-𝜏), and P-𝜏) in CSF [8,9]. Altered levels of KYNA appear in the early stages of AD, 
showing the ability to considerably impair cognitive functions, including memory disrup-
tion, which could be caused by an inflammation-induced increase in KYNA production 
in the brain [10–13]. Additionally, some experimental studies have shown several types 
of cognitive deficiencies, such as working memory deficiencies, contextual learning, major 
depressive disorders, and bipolar disorders [14–17], in response to an increased level of 
KYNA in the brain. On the other hand, a clinical study has demonstrated a positive cor-
relation between cognitive function impairments and blood-based KYNA levels in AD 
patients [18–20]. 
Considering that the physiological concentrations of KYNA in the brain and plasma 
of non-primates and primates (including humans) are usually in the nM range [21–23], a 
chronic increase in the levels of KYNA contributes by warning about the presence of im-
pairment in cognitive functions. So, there are three important factors that makes KYNA a 
very relevant AD biomarker; its presence in blood, its higher concentration, compared to 
other AD biomarkers in blood, and the most important, its altered production at the early 
stage of the disease, being an efficient biomarker in peripheral fluids for early detection 
of NDDs [24–27]. 
Nowadays, there are a few systems capable of accurately detecting KYNA in blood 
samples. In this context, the most common methods reported for the measurement of 
KYNA levels in biological matrices are based on chromatographic techniques. For in-
stance, high-performance liquid chromatography (HPLC) with electrochemical detection 
and capillary HPLC coupled with electrospray ionization and tandem mass spectrometry 
[28,29]. However, HPLC with fluorescence detection seems to be the method of choice, 
due to its high sensitivity for measuring KYNA levels in various biological samples 
[8,19,30]. 
Some enzyme-linked immunosorbent assay (ELISA) kits are commercially available 
for the quantification of this compound in biological fluids, showing sensitivities that vary 
between 4.7 and 48.8 nM (Cloud-Clone Corp., ref: CED18Ge; Antibodies Online, ref: 
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ABIN2949016). Although these kits are sensitive enough, they are quite expensive, and 
this technology is time-consuming and requires specialized personnel and equipment. 
Based on the need to go further and achieve technologies that permit AD diagnosis 
at a low cost, along with multi-analyte detection that could be miniaturized and automa-
tized for point of care (PoC) use, new approaches based on the integration of biosensors 
in lab-on-a-chip platforms are being developed, but not yet for the proposed biomarker 
candidate [30]. 
We describe in this paper the development of a robust, reliable, and non-invasive 
detection platform based on an electrochemical immunosensor for the analysis of KYNA 
concentrations in blood, to move towards an automated platform for the non-invasive 
early diagnosis of AD that contains different bioreceptors for the detection of blood bi-
omarkers in an array format. The developed KYNA sensor prototype includes two detec-
tion methods: chronoamperometry (CA) and electrochemical impedance spectroscopy 
(EIS) and it was tested in buffer and in serum. 
2. Materials and Methods 
2.1. Reagents and Instruments 
Potassium hexacyanoferrate (III), potassium hexacyanoferrate (II), 3H2O, 11-Mer-
captoundecanoic acid (MUA) (98%), 11-Mercapto-1-undecanol (MU) (97%), phosphate-
buffered saline (PBS), Tween 20, N-hydroxy-succinimide (NHS), potassium nitrate 
(KNO3), kynurenic acid (KYNA), anti-rabbit immunoglobulin G horseradish peroxidase 
(IgG-HRP) conjugate, and 3,3′,5,5′-Tetramethylbenzidine (TMB) were purchased from 
Sigma-Aldrich (St. Louis, Missouri United States). N-Ethyl-N-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDAC) and 2-(N-morpholino) ethane sulfonic acid (MES) 
were purchased from Fluka (Buchs, Switzerland). Absolute ethanol, sulfuric acid (H2SO4) 
(95–98%), sodium hydroxide (NaOH), sodium chloride (NaCl), and hydrogen peroxide 
(33%) (H2O2) were purchased from Panreac (Barcelona, Spain). Human serum was pur-
chased from Merck (Darmstadt, Germany). The immunoreagents used for KYNA detec-
tion, particularly, the polyclonal antiserum As301, used as a KYNA receptor (KYNA-Ab), 
and the bioconjugate derived from bovine serum albumin (BSA), As301/BSA-CHNH2, 
used as pseudo-KYNA labeled to BSA (BSA-pseudo-KYNA), were developed by the 
Nanobiotechnology for Diagnostics (Nb4D) group with the support of the Infraestructu-
ras Científico-Tecnológicas Singulares  (ICTS) “NANBIOSIS”, more specifically by the 
Custom Antibody Service (CAbS, CIBER-BBN, IQAC-CSIC). 
Data acquisition and analysis from cyclic voltammetry (CV), EIS, and CA were ac-
complished using EC-Lab software on an SP-150 potentiostat from BioLogic SAS.(Greno-
ble, France). 
2.2. Multi-Electrode Platform 
A matrix of 5 working electrodes (WEs) of 2 mm in diameter each was manufactured 
and integrated with a counter electrode (CE) (2.4 mm diameter) in the center of the matrix 
at the same distance from all WEs. An external reference electrode (RE) Ag/AgCl reference 
from BAS Inc. (West Lafayette, IN, USA) completed the electrochemical cell. The array 
was fabricated by photolithographic patterning of the electrodes on a low-cost and flexible 
cyclo-olefin polymer (COP), with a thickness of 200 nm of gold. This fabrication required 
two different acetate masks; the first one was necessary for the fabrication of the gold 
electrodes, and the second one for the fabrication of an insulating layer that covers the 
whole array, except for the electrodes and connecting pads, to avoid damage and unspe-
cific adsorption effects. In order to pattern the gold electrodes with the first mask, AZ 5214 
photoresist was deposited on the wafer by spin-coating at 2000 rpm, giving a film of 2.5 
μm in thickness. The wafer was then cured at 95 °C for 2 min, cooled for 10 min and then 
exposed to UV light in the mask aligner SÜSS Microtec MJB4 (Garching, Germany). The 
exposure dose was 17.3 mJ/cm2 for 11.5 s. The wet-etching of the unprotected gold was 
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performed with AZ 400K Developer for 2 min and the developer layer was removed with 
Milli-Q water. 
The insulating layer was fabricated using SU-8 2002 photoresist to achieve a highly 
resistant sensor surface, able to bear strong acid conditions required for electrode clean-
ing. This layer was made by pre-curing the wafer for 1 min at 65 °C and 1 min at 95 °C 
with the photoresist over the array and spin-coating at 3000 rpm, giving a 2 μm thickness 
of the SU-8 layer. The wafer was subjected to UV exposure in the mask aligner with the 
same dose for 4.6 s. The time and intensity of exposure were adjusted by considering the 
loss of power caused by the interposing materials, in this case the acetate masks. Then, the 
wafer was cured at 65 °C for 1 min and at 95 °C for 2 min. The wet-etching process was 
performed with SU-8 Developer for 1 min and the developer layer was removed with 
isopropanol. 
2.3. Immunosensor Construction 
Before the functionalization of the sensor surface and the electrochemical characteri-
zations, the electrodes were cleaned both chemically and electrochemically. For the chem-
ical cleaning, piranha solution was used in a ratio of 1:5 of H2O2 and H2SO4. After the 
deactivation of the solution (20 min), the electrode region was immersed in this deac-
tivated solution for 30–45 s. For the electrochemical cleaning, a ten-repetitive cyclic volt-
ammogram was performed from −0.2 V to 1.6 V, using a scan rate of 150 mV/s in a solution 
of 0.5 M H2SO4 (see Supporting Information Figure S1). 
2.3.1. Fabrication of Self-Assembled Monolayer Platform for Competitive Immunosens-
ing 
The electrochemical biosensor was constructed by immersing the array in a mixed 
solution consisting of a 1:4 solution of 5 mM MUA and 5 mM MU in absolute ethanol for 
2 h to generate a self-assembled monolayer (SAM) of these compounds on the gold elec-
trode, followed by the respective activation of its carboxyl groups by placing 200 μL of 
100 mM NHS and 300 mM EDAC in a 1:1 v/v ratio over the electrodes for 15 min. Finally, 
the electrode region was immersed in a stirred solution of 0.5 M MES buffer for 15 min, to 
clean the surface and avoid unspecific adsorption. Afterwards, 200 μL of 0.01 mg/mL of 
BSA-pseudo-KYNA was placed over the electrode surface for 1 h. Once the BSA-pseudo-
KYNA was covalently bound to the activated carboxylic groups of the SAM, a competition 
assay was performed. 
A mixture of KYNA and the primary antibody specific to the analyte, KYNA-Ab, was 
incubated on the sensor for 1 h. Based on the mechanism of this type of competitive assay, 
at higher concentrations of KYNA, there is less interaction between the KYNA-Ab and the 
BSA-pseudo-KYNA conjugate attached to the electrode’s surface. Finally, an anti-IgG-
HRP antibody (secondary-Ab) was added for 1 h for chronoamperometric measurements. 
A structural scheme of the functionalized region is shown in Figure 1. It is worth clarifying 
that between each step, a cleaning process was performed with Milli-Q water and 10 mM 
PBST, which consisted of 100 mM PBS and 5% (v/v) Tween 20. 
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Figure 1. Schematic representation of the electrochemical impedance spectroscopy (EIS) electrochemical characterization 
of the functionalized sensor. (A) Nyquist plot for each respective immobilization (blue: bare Au, red: SAM, purple: BSA-
pseudo-KYNA, black: KYNA-Ab, fuchsia: secondary-Ab). 
The sensor was tested with sterile-filtered serum from plasma type AB of a human 
male undiluted and diluted in PBS 1/10, containing known concentrations of KYNA, to 
check the sensitivity of the developed sensor in more complex matrices, closer to real sam-
ples. 
2.3.2. Experimental Setup and Electrochemical Measurements 
CV, EIS and CA were the electrochemical techniques used for the characterization of 
the developed sensor. For the CV measurements, a three-repetitive cyclic voltammogram 
was applied from −0.2 V to 0.8 V, using a scan rate of 30 mV/s. The EIS analysis was per-
formed over a range of frequencies from 1 mHz to 200 kHz, using a modulation voltage 
of 10 mV versus Ag/AgCl RE. For both CV and EIS, the measurements were performed in 
a solution of 5 mM of K3[Fe(CN)6]/K4[Fe(CN)6] in 1 M KNO3. The CA was performed by 
applying a voltage of −0.2 V for 40 s in a TMB liquid substrate solution containing hydro-
gen peroxide to monitor the peroxidase reduction present as a label in the secondary an-
tibody. For this analysis, we must consider the redox activity of KYNA, but its anodic 
potential at +1.26 V [31] is far from the applied voltage, not affecting the CA detection. 
3. Results and Discussion 
The KYNA biosensor was designed as a competitive indirect immunosensor, consid-
ering the small size of the analyte. 
This competition assay is based on the immobilization of BSA-pseudo-KYNA on the 
sensor surface that competes for the interaction of KYNA-Ab with the KYNA target. A 
higher concentration of KYNA generates a lower amount of KYNA-Ab interacting with 
BSA-pseudo-KYNA on the sensor. The presence of KYNA-Ab is measured in EIS by the 
change in the charge-transfer resistance (Rct) and in the case of CA, the addition of HRP-
labeled secondary antibody is required, which selectively interacts with KYNA-Ab and is 
detected by reduction of HRP by adding TMB and applying −0.2 V. 
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First, the sensor manufacturing steps were characterized to ensure correct bonding 
of each molecular layer on the sensor and the concentration of each of these layers was 
optimized to ensure efficient sensor performance. Finally, the KYNA detection perfor-
mance of the sensor in buffer and in serum was analyzed. 
3.1. Functionalization Optimization and Characterization of the Electrochemical Immunosensor 
CV shows high current peaks produced in the [Fe(CN)6]−4/−3 (ferricyanide) redox 
when the electrode surface is empty, which are drastically reduced when the sensor is 
functionalized with the MUA/MU SAM by effective coverage of the sensor surface. How-
ever, small differences are observed in the upper layers, as it is a limited method to char-
acterize all the manufacturing steps of the sensor (see Supporting Information, Figure S2). 
EIS measures the charge-transfer resistance and double layer capacitance generated 
in the electrochemical cell, due to the biomolecules attached to the electrode’s surface. A 
redox diffusional mediator, ferricyanide, was used in solution to enhance differences be-
tween the deposited layers, which block the ferricyanide diffusion onto the surface of the 
electrode, generating an equivalent electrical Randles circuit (1) in the electrochemical cell. 
 
(1)
where Rs is the resistance that offers the electrolyte in the solution to the current flow, Rct 
is the charge-transfer resistance produced by molecules attached on the sensor surface. Cdl 
is the double layer capacitance generated on charged surfaces like the electrode or the 
molecules attached on it and ZW is the Warburg element, an impedance related to the dif-
fusion process in a faradaic reaction, in this case due to the presence of ferricyanide [32]. 
Each layer deposited on the electrode surface is visible due to an increase in Rct, related to 
the thickness and coverage of the layer, which hinders the electron transfer from the fer-
ricyanide. A typical Nyquist plot can be observed in Figure 1, along with the rise in the 
values of the Rct, due to the increased layers of biomolecules immobilized on the surface. 
Nyquist plots were fitted with the Randles model to obtain Rct and Cdl values. 
We first characterized the bare sensor, where there was negligible obstruction for the 
ferricyanide redox molecules to reach the electrode surface. Then, the gold was covered 
by the self-assemblage of thiolated linkers, through which strong molecules bring an an-
choring site for the next layer and protection against nonspecific fouling of unwanted 
molecules.  
Considering that the electron transfer reaction from ferricyanite occurs only in bare 
areas on the electrode surface, then the Rct can be correlated to the apparent fractional 





where Γ is the surface coverage, RctAu is the Rct on the bare electrode and RctSAM is the Rct 
under the same conditions measured on the MU/MUA functionalized electrode. Accord-
ing to the Nyquist plots results, a surface coverage value of 0.83 (n = 5) was calculated. 
This efficient coverage of the electrodes provides a large and homogeneous surface 
binding site density for the BSA-pseudo-KYNA molecules. 
Afterwards, the carboxylic anchoring sites from the MUA were activated as NHS es-
ters for its subsequent interaction with the free available amino groups of the BSA-pseudo-
KYNA. In this bioconjugate, the BSA protein incorporates the hapten CHNH2, which is a 
structurally related KYNA compound, allowing its recognition by the antibody produced 
against KYNA. The immobilization of this bioconjugate (approx. 3–5 nm in diameter) was 
clearly observed on the sensor surface, producing a 25-times higher ferricyanide blockage 
than the previous SAM layer. Next, KYNA-Ab interactions were also readily noticed by 
the increase in electrode impedance, as shown in Figure 1. 
Biosensors 2021, 11, x FOR PEER REVIEW 7 of 16 
 
Optimizing the concentration of the deposited biomolecules on each functionaliza-
tion step of the sensor will significantly improve its final sensitivity and selectivity to 
KYNA. Therefore, several concentrations of KYNA-Ab were analyzed. Since a competi-
tive assay is required, it is worth clarifying that each characterization was performed in 
the absence of KYNA, to ensure BSA-pseudo-KYNA/KYNA-Ab interactions and the sub-
sequent binding with the secondary-Ab. 
3.1.1. Effect of BSA-Pseudo-KYNA Concentration 
The homogeneous distribution and orientation of BSA-pseudo-KYNA has a marked 
influence on the sensor sensitivity and selectivity. EIS can provide this important infor-
mation, while CA is very relevant to determine the amount of bioreceptors attached to the 
sensor’s surface. Therefore, these two techniques were employed to characterize the opti-
mum concentrations of BSA-pseudo-KYNA. On the one hand, the characterization of the 
sensor surface with EIS was carried out by measuring the charge transfer resistance on the 
surface of the functionalized sensor, which hinders the transfer of ferrocyanide electrons. 
On the other hand, chronoamperometry measures the current produced by the reduction 
of the HRP label attached to the secondary antibody. 
The results obtained with CA are shown in Figure 2A. At first, there was an increase 
in the current from 4.42 to a maximum of 4.47 μA when the concentration of bioconjugate 
on the surface was increasing. However, concentrations higher than 0.01 mg/mL caused a 
decreasing signal behavior because a higher concentration of biomolecules in solution 
may disrupt the tidy formation of the monolayer, making it counterproductive. The re-
sults obtained with EIS, in Figure 2B, confirmed this behavior and the aforementioned 
Gauss distribution was even clearer, with a maximum Rct of 600.02 kΩ. Therefore, the op-
timum concentration for this biomolecule layer was 0.01 mg/mL. 
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Figure 2. Chronoamperometry (CA) and EIS characterization of the optimization of the biosensor’s different layers. (A,B) 
BSA-pseudo-KYNA concentration optimization for sensor functionalization, characterized by CA and EIS, respectively; 
(C) KYNA-Ab concentration optimization using EIS in the characterization; (D) secondary-Ab concentration optimization 
characterized with CA. 
3.1.2. Effect of KYNA-Ab Concentration 
The KYNA-Ab plays a pivotal role on the selectivity of the biosensor because it can 
bind to the corresponding epitope of either the BSA-pseudo-KYNA conjugate or the 
KYNA analyte, which will greatly influence the resulting current signal and the ability of 
the sensor to detect low KYNA concentrations. As this is a competitive assay, the antibod-
ies that bind to the BSA conjugate are the ones producing an increase in Rct in EIS or an 
increase in current signal in CA, after the anti-IgG-HRP conjugate interacts in the system. 
To optimize the concentration of this antibody, the sensor response was investigated with 
different dilutions in 10 mM PBST. 
As can be seen in Figure 2C, the higher the KYNA-Ab concentration, the higher the 
sensor response, down to a saturation point on dilutions over 1/8000 with a maximum 
current of 4.55 μA (see Supporting Information Figure S3A). This is because, at this dilu-
tion ratio, there would be no more epitopes for the binding of the antibody; thus, the un-
bound molecules would be washed away. The same behavior was seen in the EIS meas-
urement, in which the Rct value is kept almost constant after it achieves the saturation 
point on dilutions over 1/8000 with a maximum Rct of 738.1 kΩ. 
Based on these results, the optimum dilution ratio of the primary antibody was 
1/8000. This concentration was used for further optimizations. 
3.1.3. Effect of Secondary Antibody Concentration 
The anti-IgG-HRP conjugate is a crucial biomolecule for the biosensor response, since 
it introduces the enzymatic label required for the CA measurement. Five different dilu-
tions were also tested, and the same behavior as the primary antibody was seen. As ex-
pected, the anti-IgG-HRP conjugate only binds to the KYNA-Ab, and therefore has the 
same tendency. As shown in Figure 2D, at dilutions lower than 1/6000, a saturation of the 
sensor signal was also experienced, with a maximum current of 4.61 μA obtained in CA 
and a maximum of 800.12 kΩ Rct in EIS (see Supporting Information Figure S3B). Both 
CA and EIS measurements proved this behavior. Therefore, the chosen dilution ratio for 
this antibody was 1/6000. 
3.2. Study of Biosensor’s Performance 
3.2.1. Selectivity Study 
To study the sensor signal specificity, and detect the undesired nonspecific adsorp-
tion of other molecules, several controls were performed. It is worth clarifying that every 
control included all the sensor steps, except the one present in the control name. 
In a competitive assay, the presence of the target (Complete, Figure 3) corresponded 
to the lowest signal compared with the absence of KYNA (Control no KYNA, Figure 3), 
where KYNA-Ab was bound to the BSA-pseudo-KYNA on the surface instead of the tar-
get, as can be appreciated by the remarkably higher signal obtained from this control. 
The other controls were in a low range of current signal. The control without BSA-
pseudo-KYNA (Control no BSA-pseudo-KYNA, Figure 3) provided the signal corre-
sponding to the nonspecific absorption of KYNA-Ab and secondary-Ab on the sensor sur-
face. This high signal was due to the excellent properties of BSA as an unfolding agent. 
However, this control did not affect the sensor performance, since BSA-pseudo-KYNA 
would be present on the surface of our sensor. Meanwhile, the control without KYNA-Ab 
(Control no KYNA-Ab, Figure 3) was related to a low nonspecific adsorption of anti-IgG-
HRP. The last control (Control no secondary-Ab, Figure 3) was related to the background 
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noise from the CA detection, where no anti-IgG-HRP was added, and thus no amperomet-
ric label (HRP) is present on the sensor. 
 
Figure 3. KYNA immunosensor selectivity test characterized with CA. A scheme of the results 
represents the possible molecules on the sensor surface and washed out after incubation. 
3.2.2. Sensitivity Study 
Based on the results obtained in the optimization of the concentration of each immu-
noreagent, the sensitivity and linearity in the KYNA detection of the developed electro-
chemical immunosensor were evaluated by two different techniques, CA and EIS, using 
different concentrations of KYNA standard (0, 10 pM, 100 pM 1 nM, 10 nM, 100 nM, and 
1000 nM) and five repetitions of each one. Each concentration of KYNA was mixed with 
KYNA-Ab and incubated on the sensor, where the BSA-pseudo-KYNA was immobilized. 
In the case of CA, incubation with labeled secondary-Ab HRP and the addition of TMB 
are also required. In CA, the values were normalized based on the blank value.  
In CA, the current decreased as KYNA concentrations increased (Figure 4A). In a 
competition assay, the KYNA-Ab competes for the interaction of the analyte and the BSA-
pseudo-KYNA, producing a lower amount of KYNA-Ab on the sensor surface at a higher 
concentration of KYNA. Therefore, a lower current is produced by a smaller amount of 
secondary-Ab-HRP attached to the sensor surface. The linear region was evident within 
the sensor working range of 0.01–100 nM with a current range of 4.93 to 0.18 μA and a 
calibration equation of I(μA) = 2.32 − 0.499 log C(nM) and an excellent correlation coeffi-
cient of 0.9987, with n = 5. The limit of detection (LOD) was calculated considering a 99.9% 
confidence level (k = 3) and K 10 for the limit of quantitation (LOQ) (Long; 1983), obtaining 
an LOD of 16.9 pM and 91 pM for the LOQ in the immunosensor KYNA detection with 
CA in buffer.  
Similar calculations were done for the EIS results, and the behavior observed in this 
technique was comparable to CA, as shown in Figure 4B. There was a decrease in Rct when 
the concentration of KYNA increased. In this case, the Rct is produced by the presence of 
KYNA-Ab adhered to the surface of the sensor, which hinders the electron transfer of 
ferricyanide. Therefore, the higher concentration of KYNA reduces the presence of 
KYNA-Ab on the sensor surface, resulting in a lower Rct. 
A linear regression was done for the same range of concentrations, obtaining an Rct 
range of 848.14 to 799.51 kΩ, with a calibration equation of Rct(kΩ) = 23.8 − 4.88 log C(nM) 
with an excellent correlation coefficient of 0.9921 (n = 5). 
Additionally, a low LOD of 37.6 pM and an LOQ of 1.22 nM were obtained. Accord-
ing to the values obtained for the LOD and LOQ in both techniques, it can be concluded 
that the CA can provide a better sensing of KYNA under buffered conditions. However, 
the main drawback of this technique, compared to the EIS, is that it requires an extra 
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immobilization step of the anti-IgG-HRP conjugate after the KYNA-Ab. Therefore, CA is 
more time-consuming and less cost-effective than EIS, and requires extra reagents, i.e., 
anti-IgG-HRP and TMB, to label the analyte interaction. 
EIS can be more easily adapted to a lab-on-a-chip device since it is label free and 
needs fewer steps and reagents for sensing. Therefore, the EIS technique could be consid-
ered as a better sensing technique with an excellent LOD for KYNA in buffer conditions. 
This sensor offers an excellent platform to construct a low-cost and easy-to-use array, able 
to perform diagnosis based on KYNA detection. 
 
Figure 4. KYNA immunosensor sensitivity test in buffer. The calibration curves were performed 
with CA (A) and EIS (B). The concentrations considered were 0, 10 pM, 100 pM 1 nM, 10 nM, 100 
nM, and 1000 nM (n = 5). 
3.2.3. Determination of KYNA in Human Serum Samples 
With the aim to test the sensitivity of the developed sensor in more complex matrices, 
closer to real samples, the measurements were also performed in undiluted human serum. 
The same range of KYNA concentrations was used. A summarizing table with the KYNA 
LOD and LOQ in buffer, serum, and 1/10 serum dilution measured by CA and EIS is pre-
sented in the Supporting Information (Table S1). 
A clear difference observed from the results with serum (Figure 5) compared with 
buffer KYNA detection is the higher dispersion of the results, with the immediate out-
come of a standard deviation increment of about 10 times in serum. Considering the pres-
ence of multiple biomolecules in the serum samples, these molecules are a new variable 
affecting on the sensor response. Consequently, the LOD in CA and EIS detection is also 
impaired. As can be seen in Figure 5A, the LOD obtained in serum for CA was approx. 50 
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times higher than the LOD in buffer; 818.1 pM vs. 16.9 pM, respectively. An evident linear 
region within the same working range (0.01–100 nM) was observed, with a calibration 
equation of I(μA) = 37.172 − 6.1874 log C(nM), with an excellent correlation coefficient of 
0.9913 (n = 5). 
This increment in the LOD could be due to the complex nature of the matrix, which 
contains a high level of interfering compounds that interact with the antibody receptor 
[34] and the nonspecific adsorption of matrix proteins that cover the BSA-pseudo-KYNA, 
reducing the binding options for KYNA-Ab and anti-IgG-HRP, with the consequent de-
crease in the sensor sensitivity [35, 36]. 
As observed in the CA measurement, there was also a remarkable increase in the 
LOD of EIS in serum (365 pM) (Figure 5B), which it was almost 10 times more than in 
buffer (37 pM). The evident linear region within the same working range has a calibration 
equation of Rct(kΩ) = 125.81 − 28.168 log C(nM), with a good correlation coefficient of 
0.9829 (n = 5). 
The greater effect of the matrix on CA sensitivity than in EIS may be due to pas-
sivation with nonspecific adsorbed molecules that block the electron transfer from the re-
dox label to the electrode and the presence of redox active molecules in the serum matrix 
that interfere in HRP detection. 
 
Figure 5. KYNA immunosensor sensitivity test. (A,B) Calibration curves in undiluted human serum, using CA and EIS, 
respectively, and (C,D) calibration curves in 1/10 diluted human serum in phosphate-buffered saline (PBS), using CA and 
EIS, respectively. The concentrations considered were 0, 10 pM, 100 pM 1 nM, 10 nM, 100 nM, and 1000 nM (n = 5). 
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This increase in Rct is mainly due to the nonspecific adsorption of some component 
of the serum on the surface of the electrode. The thickness of this layer of undesired ad-
sorbed molecules increases the current resistance in the electrode. Additionally, this new 
layer blocks the BSA-pseudo-KYNA interaction points with the KYNA-Ab. Thus, the 
KYNA-Ab binding is lower and the recorded Rct has a higher background signal from the 
nonspecific adsorption of serum molecules, making it less detectable and reducing the 
sensitivity of the sensor. However, the nonspecific layer formed by the serum has much 
less impact in Rct recorded with EIS than the one in CA. 
As can be seen in Figure 5C,D, when the undesired layer of molecules from the serum 
is reduced, diluting this sample 1/10, there is a significant decrease in the matrix effect that 
is causing the serum insulation on the sensor, obtaining a much better LOD from both 
techniques; 391.71 pM for CA and 278.8 pM for EIS. 
For the CA measurement, a calibration equation of I(μA) = 25.369 − 4.374 log C(nM), 
with an excellent correlation coefficient of 0.9848 (n = 5), and in the case of EIS, a calibration 
equation of Rct(kΩ) = 163.23 − 31.557 log C(nM), with a correlation coefficient of 0.9791 (n 
= 5), were obtained. 
Based on these results, it was necessary to evaluate the nonspecific serum interfer-
ences occurring on the electrode. For this purpose, the sensor platform modified with 
SAM and BSA-pseudo-KYNA was put into contact with the serum (without the antibody 
addition step), to determine the grade of protein adsorption on the surface. 
This approach was done using the two techniques, and the results are shown in Fig-
ure S4 (see Supporting Information). In these results, the remarkably high resistance that 
was generated by the adsorption of serum proteins is evident, which reduced the analyte 
interaction properties of the sensor. This fact was even more appreciated with an incuba-
tion with the secondary-Ab, and its nonspecific adsorption followed the same trend as the 
serum adsorption, as shown in the CA detection. As expected, this behavior diminished 
when a 1/10 serum dilution was done. This dilution of the KYNA concentration was al-
ready considered for the calculation of the LODs. 
Even with this increase in the LODs observed in serum, this sensor platform has an 
excellent sensitivity and working range, for the appropriate detection of KYNA in blood 
for AD diagnosis. 
Based on the studies reported in the literature about the detection of this specific bi-
omarker in a blood-based scenario, it is valid to state that the electrochemical immunosen-
sor developed in this study presents an excellent LOD. As mentioned in the introduction, 
HPLC is the current gold standard technique to determine KYNA with different detectors, 
such as fluorometric and electrochemical. By using an HPLC coupled with a fluorescence 
detector, the concentrations obtained for KYNA in human serum for a control group and 
AD patients were 30.94 ± 13.18 nM and 20.85 ± 8.23 nM, respectively [20]. Commercially 
available ELISA kits have also been used for this purpose, giving LODs varying between 
4.7 and 48.8 nM (Cloud-Clone Corp., ref: CED18Ge; Antibodies Online, ref: 
ABIN2949016). A recent study reported an optimal cut-off point for the determination of 
KYNA of 39.96 nM in CSF [9]. In plasma, KYNA was also considered a significant predic-
tor of AD. A preclinical study of patients with AD demonstrated a higher content of 
KYNA (above 50 nM) compared to healthy participants [37]. 
The developed electrochemical immunosensor has demonstrated a lower LOD, of 
278.8 pM, with EIS in diluted serum samples than that reported in the literature for KYNA 
detection with serum samples, which is about 17 times lower than the lowest LOD re-
ported. Moreover, these outstanding results have been achieved with a label-free config-
uration, that requires fewer steps and reagents and it is performed with EIS electrochem-
ical detection, which makes this technology easy to miniaturize, automatize, and integrate 
in a multiplexed platform at a low cost, which are features required for PoC development. 
This work takes us a step closer to a multiple array analysis integrated for PoC diag-
nosis of AD in blood. This low-cost technology brings the possibility of a massive test of 
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AD before symptoms appear to achieve an early detection of this disease, which is critical 
to achieve a high likelihood of AD cure. 
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3.2.4. Reproducibility Analysis of the Sensor 
We obtained good reproducibility, with is low standard deviation with five repeti-
tions, when the sensor was tested under controlled conditions of standard buffer solution; 
4.86 ± 0.12 μA (for 0.01 mM of KYNA measured with CA in buffer), which is 2.46% of the 
signal measured. However, when the sensor was tested in serum samples, a more complex 
matrix came into play, resulting in an increase in the standard deviation of the measure-
ment in both detection methods; 77.18 ± 10.9 μA (for 0.01 mM of KYNA measured with 
CA in 1/10 serum), which is 10.95% of the signal measured, and 118.45 ± 14.0 μA (for 0.01 
mM of KYNA measured with CA in serum), which is 11.82% of the signal measured. 
The lower sensor signal (higher KYNA concentration) also increases the standard de-
viation. For example, in CA detection in 1/10 serum, a lower signal was obtained with 
1000 nM; 34.10 ± 6.21 μA has a higher standard deviation (18.21%) than that obtained with 
0.01 nM; 77.18 ± 8.45 μA (10.95%). The same tendency is observed in the different sample 
matrices tested and detection methods used. 
Moreover, it is important to point out the large differences in reproducibility ob-
served with EIS compared with CA, using the same sensor in all the sample matrices 
tested, but with different methods of detection. Comparing the 0.01 mM analysis in buffer 
of KYNA, EIS is almost 10 times more reproducible than CA; 847.59 ± 2.43 kΩ (0.28%) and 
4.86 ± 0.12 μA (2.47%), respectively. Reproducibility is another important feature that 
makes EIS a better candidate for KYNA detection. 
4. Conclusions 
This work has demonstrated an effective immunosensor platform for the detection 
in buffer and human serum samples of KYNA, which is considered a blood-based bi-
omarker candidate for AD. 
The EIS characterization of the sensor fabrication steps demonstrated an optimal sur-
face coverage of 0.83 for the MU/MUA SAM and a good immobilization of all sensor lay-
ers. 
The results obtained suggest a highly reproducible detection by EIS with 0.28% of the 
signal, an increased value in CA measurements (2.47%) and in samples with serum matrix 
(11.82%, for the same KYNA concentration in CA). 
A good sensitivity and a high molecular specificity were successfully reached by op-
timizing each biosensor layer concentration. This platform has demonstrated an excellent 
LOD; 16.9 pM and 37.6 pM for CA and EIS, respectively, in buffer, which is the lowest 
LOD reported in the literature for KYNA detection. The measurements done in human 
serum confirm the performance of the sensor when complex matrices are used. The non-
specific matrix interference was minimized by a 1/10 serum dilution, obtaining an LOD of 
391.7 pM and 278.8 pM for CA and EIS, respectively. 
With such results, it was possible to demonstrate good reproducibility and selectiv-
ity, as well as excellent sensitivity of the developed biosensor, in an appropriate working 
range for KYNA detection correlated with AD diagnosis. 
Considering that CA is less reproducible and more time- and reagent-consuming, it 
is less cost-effective than the EIS technique. Based on the advantages EIS has over CA, EIS 
has been chosen as the recommended technique for this particular immunosensor appli-
cation. 
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